-
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
-
We accelerate discovery and development of the next generation of targeted and immune-based therapies
-
We integrate academic and industrial research to drive clinical trials and improve patients’ lives
The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
Spotlight
Twitter feed
A group of distinguished oncology leaders from countries in the Asia Pacific region are advising on the needs of our members & facilitating member involvement in global activities. https://t.co/YwWLmDlNJE #ASCOconnection #ASCOInternational
“The payoffs of cancer prevention are huge."
ICYMI: #AACRFellows and Past President @Rndubois shared his predictions for the field of cancer prevention in 2021.
Learn more on the #AACRBlog:
https://t.co/e84l1fjwDV
Experiencing bias based on her accent only strengthened Dr. Viju Chandrasekhar's resolve to fight injustice and be a mentor to international medical graduates #ASCOconnection

”Speak Better”: Stripes and Swipes of a Global Language
"My motto is to stand up for all the people who face casual racism, sexism, and injustice, and my aim is to protect international trainees in medicine...
fal.cn
.@US_FDA today approved Melflufen for the treatment of adult patients with triple-class refractory multiple #myeloma
Dana-Farber’s Paul Richardson, MD, comments on what this approval means for patients 👇
.@rschilsky Bids Adieu to ASCO — As chief medical officer, he made oncologist group into an important research engine. By @icingram via @medpagetoday

Richard Schilsky Bids Adieu to ASCO
As chief medical officer, he made oncologist group into an important research engine
fal.cn
Learn more about our recently issued guideline on the clinical management of #dyspnea in adult patients w advanced cancer #ASCODailyNews

ASCO Issues Guideline on Dyspnea in Advanced Cancer
ASCO has issued a new guideline on the clinical management of dyspnea in adult patients with advanced cancer.
fal.cn
February is National Cancer Prevention Month. AACR Active members receive free access to one AACR journal and reduced subscription rates to all other journals— including our two prevention journals, @CEBP_AACR and @CAPR_AACR. Learn more:
https://t.co/vEcbcfSYMz
Genomic architecture and targets in hypoxic tumors:
Robert G. Bristow @OfficialUoM will address this topic in a keynote address at the AACR virtual conference on Radiation Science and Medicine, March 2-3. Learn more:
https://t.co/a9YnG3silN
#AACRrsm21
Sirtuins, Cell Homeostasis, and Metabolism:
David Gius @UTHealthSA, @carmenbergom @WUSTL, Fen Xia @UAMS, and Douglas R. Spitz @uiowa will discuss this topic at the AACR virtual conference on Radiation Science and Medicine, March 2-3:
https://t.co/3PUsxXSf7Z
#AACRrsm21
Thanks to the generous support of a new funding partner, @ConquerCancerFd developed a program aimed at recruiting and retaining young physician-scientists committed to research in symptom management #ASCOconnection

Conquer Cancer, Rising Tide Foundation for Clinical Cancer Research
Conquer Cancer, the ASCO Foundation, has a new funding partner for a program aimed at recruiting and retaining young physician-scientists committed to...
fal.cn
Recent publications
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy.
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell.
Announcements
We’re pleased to share a new section on our site, “Our stories,” which will profile staff from the Belfer team. Our first story is Sarah Musoke (Nzikoba). Read Sarah’s story.
Strategic alliances

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients
Donor highlight
Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.
